Ranbaxy Denies Fraudulent Conduct Alleged By U.S. FDA As Rumors Swirl About Daiichi Deal
This article was originally published in PharmAsia News
Executive Summary
Ranbaxy has denied U.S. FDA allegations that it conducted "systematic fraudulent conduct" related to concealing violations of current good manufacturing practices